PHE, which conducted an independent evaluation of Roche's antibody test last week, said it found Roche's assay has a specificity of 100%.
With Zelboraf, a drug that targets specific mutations in cancer cells, eight out of 10 patients in an early-stage trial experienced significant tumor shrinkage. Roche clearly had a remarkable drug, though it only worked for people with a specific genetic makeup.
In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma said," In a patently challenged issue, the innovator is bound to protect his rights and this can be done only through the mechanism of suing.There is nothing extra-ordinary about it."
Roche more cautious on 2011 on healthcare reforms